Cytochrome 2C19 Enzyme Polymorphism Frequency in Different Indigenous Ethnic Groups in Russian Federation: A Systematic ReviewKarin Mirzaev1*, Dmitriy Sychev2, Goar Arutyunyan1, Alla Yugay1 and Denis Andreev3
- *Corresponding Author:
- Karin Mirzaev
I.M. Sechenov First Moscow State Medical University
Moscow, Russian Federation, Trubetskaya 8 street
119991 Moscow, Russian Federation
E-mail: [email protected]
Received date: April 24, 2014; Accepted date: June 27, 2014; Published date: July 04, 2014
Citation: Mirzaev K, Sychev D, Arutyunyan G, Yugay A, Andreev D (2014) Cytochrome 2C19 Enzyme Polymorphism Frequency in Different Indigenous Ethnic Groups in Russian Federation: A Systematic Review J Pharmacogenomics Pharmacoproteomics 5:136. doi: 10.4172/2153-0645.1000136
Copyright: © 2014 Mirzaev K, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Background and objective: Genetically determined diversity in the activity of cytochrome P450 (CYP) – enzyme regulating the biotransformation of drugs and xenobiotics – is one of the main causes of interindividual differences in response to pharmacotherapy. The objective of this review is to analyze the prevalence of polymorphic markers of gene CYP2C19, associated with the violation of the pharmacological response to clopidogrel among the various ethnic groups living in the Russian Federation.
Methods: A literature review was conducted using the following databases: MEDLINE and eLIBRARY.RU. Russian language articles published between 20032003 (the first publication in Russians) and 2014 were reviewed.
Results: The authors detected 11 original research studies on CYP2C19 gene in 11 indigenous ethnic groups of Russian Federation. According to the research data, the frequency of CYP2C19*2 and CYP2C19*3 markers prevalence is higher in the Mongolian race (with maximum CYP2C19*2 frequency in the Kalmyks - 25, 0 % and CYP2C19*3 in Tatars – 21,0 %). CYP2C19*17 allele has been studied only in Russians, and was about the same as in the Caucasian race (14,0 %).
Conclusion: The results of the investigation will be beneficial for developing guidelines for CYPC19 genotype– directed antiplatelet therapy for each region of Russia.